Evidence map›Paper›PMID 42358969›Full record

ArticleFrontiers in immunology2026

Human NKT10 cells are enriched in cord-derived invariant natural killer T cells and mediate immune-regulation in a xenogeneic graft-versus-host disease model.

Abel Trujillo-Ocampo, Pamella Borges, Maison Grefe, Martiela Vaz de Freitas, Sung-Eun Lee, Yuan Qi, Jelita Clinton, Dan Li, Hong He, Ling Yu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Abel Trujillo-OcampoDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Pamella BorgesDepartment of Biology and Biochemistry, The University of Houston, Houston, TX, United States.
Maison GrefeDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Martiela Vaz de FreitasDepartment of Biology and Biochemistry, The University of Houston, Houston, TX, United States.
Sung-Eun LeeDepartment of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Yuan QiDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jelita ClintonDepartment of Therapeutic Discovery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Dan LiDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Hong HeDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Ling YuDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Arnau Peris-CuestaDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Erik A EhliAvera McKennan Hospital and University Health Center, Sioux Falls, SD, United States.
Qing MaDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Xiaoping SuDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Dinler Amaral AntunesDepartment of Biology and Biochemistry, The University of Houston, Houston, TX, United States.
Gheath Al-AtrashDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jeffrey J MolldremDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Elizabeth J ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jin S ImDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD1d-restricted invariant natural killer (iNK) T cells are innate T cells known for their ability to shape adaptive immunity toward inflammation or immune-suppression via the rapid production of Th1-, Th2-, and Th17-type cytokines from corresponding iNKT subsets such as NKT1, NKT2, and NKT17. IL-10-producing invariant NKT cells, termed NKT10 cells, are thought to play an immunoregulatory role, but their potential clinical use remains underexplored. We characterized human NKT10 cells from cord-derived iNKT cells and investigated their therapeutic utility in allogeneic stem cell transplantation. Cord and cord-derived iNKT cells contained a high frequency of CD4

Indexed as

Fetal BloodGraft vs Host DiseaseNatural Killer T-CellsAnimalsCytokinesDisease Models, AnimalHumansMiceTransplantation, HeterologousCytokinescord-derived iNKT cellsGvHDimmune-regulationNKT10transplantation

Identifiers

PMID42358969
PMCPMC13291024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.